Roche leaves $$$ on the table

ABSC, which is developing and marketing drug discovery technologies, was the second biotech follow-on pulled this week, further marking the narrowing of the biotech financing window. On Tuesday, combinatorial technology company Symyx (SMMX) withdrew its 1.25 million-share follow-on, citing market conditions and volatility.